{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:38:15Z","timestamp":1791905895308,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102173"],"award-info":[{"award-number":["82102173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102173"],"award-info":[{"award-number":["82102173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102173"],"award-info":[{"award-number":["82102173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China under Grants","award":["12275162"],"award-info":[{"award-number":["12275162"]}]},{"name":"Academic promotion program of Shandong First Medical University","award":["2019LJ004"],"award-info":[{"award-number":["2019LJ004"]}]},{"name":"Taishan Scholars Program of Shandong Province","award":["ts20120505"],"award-info":[{"award-number":["ts20120505"]}]},{"name":"Shandong Medical Association Clinical Research Fund\u2014Qilu Special Project","award":["YXH2022ZX02198"],"award-info":[{"award-number":["YXH2022ZX02198"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis of patients undergoing hepatectomy combined with transarterial chemoembolization (TACE) and TACE alone was examined in order to better understand the role of hepatectomy in the treatment of hepatocellular carcinoma (HCC). In this work, we also created a model and investigated the variables influencing overall survival (OS) in HCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of 1083 patients who received TACE alone as the control group and 188 patients who received TACE after surgery in a total of 1271 HCC patients treated with LR\u2009+\u2009TACE or TACE at three third-class hospitals in China. It was done using the Propensity Score Matching (PSM) technique. The differences in OS between the two groups were compared, and OS-influencing factors were looked at. The main endpoint is overall survival. In this study, the COX regression model was used to establish the nomogram.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median OS of the LR\u2009+\u2009TACE group was not attained after PSM. The median OS for the TACE group was 28.8\u00a0months (95% CI: 18.9\u201338.7). The median OS of the LR\u2009+\u2009TACE group was higher than that of the TACE group alone, indicating a significant difference between the two groups (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200916.75,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). While it was not achieved in the LR\u2009+\u2009TACE group, the median OS for patients with lymph node metastases in the TACE group alone was 18.8\u00a0months. The two groups differed significantly from one another (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20094.105,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.043). In patients with distant metastases, the median OS of the LR\u2009+\u2009TACE treatment group was not achieved, and the median OS of the TACE group alone was 12.0\u00a0months. The difference between the two groups was sizable (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20095.266,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022). The median OS for patients with PVTT following PSM was 30.1\u00a0months in the LR\u2009+\u2009TACE treatment group and 18.7\u00a0months in the TACE alone group, respectively. The two groups differed significantly from one another (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20095.178,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023); There was no discernible difference between the two groups in terms of median overall survival (OS), which was 30.1\u00a0months for patients with lymph node metastasis and 19.2\u00a0months for those without (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05); Regarding the median OS for patients with distant metastases, which was not achieved and 8.5\u00a0months, respectively, there was a significant difference between the two groups (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20095.759,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.016). We created a new nomogram to predict 1-, 2-, and 3-year survival rates based on multiple independent predictors in COX multivariate analysis. The cohort's C-index is 0.705. The area under the curve (AUC value) for predicting 1-, 2-, and 3-year survival rates were shown by the subject operating characteristic (ROC) curve linked to the nomogram to be 0.730, 0.728, and 0.691, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LR\u2009+\u2009TACE can increase OS, delay tumor recurrence, and improve prognosis in HCC patients when compared to TACE alone. Additionally, the nomogram we created does a good job of forecasting the 1-year survival rate of hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-023-02886-1","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:02:10Z","timestamp":1693890130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Xin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"6","key":"2886_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/cells9061370","volume":"9","author":"F Pi\u00f1ero","year":"2020","unstructured":"Pi\u00f1ero F, Dirchwolf M, Pess\u00f4a MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020;9(6):1370. https:\/\/doi.org\/10.3390\/cells9061370. Published 2020 Jun 1.","journal-title":"Cells"},{"issue":"3","key":"2886_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2886_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","volume":"260","author":"JH Zhong","year":"2014","unstructured":"Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329\u201340. https:\/\/doi.org\/10.1097\/SLA.0000000000000236.","journal-title":"Ann Surg"},{"issue":"Supplementum 3","key":"2886_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14735\/amko20203S30","volume":"33","author":"T V\u00e1clav","year":"2020","unstructured":"V\u00e1clav T. Surgical treatment of hepatocellular carcinoma. Chirurgick\u00e1 l\u00e9\u010dba hepatocelul\u00e1rn\u00edho karcinomu. Klin Onkol. 2020;33(Supplementum 3):30\u20133. https:\/\/doi.org\/10.14735\/amko20203S30.","journal-title":"Klin Onkol"},{"issue":"3","key":"2886_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cnc.2022.04.004","volume":"34","author":"H Gilles","year":"2022","unstructured":"Gilles H, Garbutt T, Landrum J. Hepatocellular carcinoma. Crit Care Nurs Clin North Am. 2022;34(3):289\u2013301. https:\/\/doi.org\/10.1016\/j.cnc.2022.04.004.","journal-title":"Crit Care Nurs Clin North Am"},{"key":"2886_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.radonc.2019.05.006","volume":"140","author":"J Sun","year":"2019","unstructured":"Sun J, Yang L, Shi J, et al. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: an open-label randomized controlled trial. Radiother Oncol. 2019;140:20\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2019.05.006.","journal-title":"Radiother Oncol"},{"key":"2886_CR7","doi-asserted-by":"publisher","unstructured":"Lucatelli P, De Rubeis G, Rocco B, et al. Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study [published correction appears in BMC Gastroenterol. 2021;21(1):282]. BMC Gastroenterol. 2021;21(1):51. https:\/\/doi.org\/10.1186\/s12876-021-01631-w.\u00a0Published 2021 Feb 3.","DOI":"10.1186\/s12876-021-01631-w"},{"issue":"3","key":"2886_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.14735\/amko2020214","volume":"33","author":"T Rohan","year":"2020","unstructured":"Rohan T, Uher M, Matkul\u010d\u00edk P, et al. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Prognostick\u00e9 faktory p\u0159e\u017eit\u00ed u pacient\u016f s hepatocelul\u00e1rn\u00edm karcinomem l\u00e9\u010den\u00fdch pomoc\u00ed transarteri\u00e1ln\u00ed chemoembolizace. Klin Onkol. 2020;33(3):214\u20139. https:\/\/doi.org\/10.14735\/amko2020214.","journal-title":"Klin Onkol"},{"key":"2886_CR9","doi-asserted-by":"publisher","unstructured":"European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma [published correction appears in J Hepatol. 2012 Jun;56(6):1430]. J Hepatol. 2012;56(4):908\u2013943. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.001.","DOI":"10.1016\/j.jhep.2011.12.001"},{"issue":"1","key":"2886_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.31022","volume":"72","author":"G Han","year":"2020","unstructured":"Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology. 2020;72(1):198\u2013212. https:\/\/doi.org\/10.1002\/hep.31022.","journal-title":"Hepatology"},{"issue":"3","key":"2886_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/hep.29883","volume":"68","author":"MH Hyun","year":"2018","unstructured":"Hyun MH, Lee YS, Kim JH, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology. 2018;68(3):977\u201393. https:\/\/doi.org\/10.1002\/hep.29883.","journal-title":"Hepatology"},{"key":"2886_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","volume":"3","author":"AJ Vickers","year":"2019","unstructured":"Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res. 2019;3:18. https:\/\/doi.org\/10.1186\/s41512-019-0064-7. Published 2019 Oct 4.","journal-title":"Diagn Progn Res"},{"issue":"2","key":"2886_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cam4.3613","volume":"10","author":"B Yan","year":"2021","unstructured":"Yan B, Su BB, Bai DS, et al. A practical nomogram and risk stratification system predicting the cancer-specific survival for patients with early hepatocellular carcinoma. Cancer Med. 2021;10(2):496\u2013506. https:\/\/doi.org\/10.1002\/cam4.3613.","journal-title":"Cancer Med"},{"issue":"1","key":"2886_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF02603032","volume":"16","author":"JH Park","year":"1993","unstructured":"Park JH, Han JK, Chung JW, Han MC, Kim ST. Postoperative recurrence of hepatocellular carcinoma: results of transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol. 1993;16(1):21\u20134. https:\/\/doi.org\/10.1007\/BF02603032.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"2886_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4254\/wjh.v7.i1.40","volume":"7","author":"ZH Gao","year":"2015","unstructured":"Gao ZH, Bai DS, Jiang GQ, Jin SJ. Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma. World J Hepatol. 2015;7(1):40\u20133. https:\/\/doi.org\/10.4254\/wjh.v7.i1.40.","journal-title":"World J Hepatol"},{"issue":"6","key":"2886_CR16","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2214\/AJR.14.13343","volume":"204","author":"QQ Zu","year":"2015","unstructured":"Zu QQ, Liu S, Zhou CG, et al. Chemoembolization of recurrent hepatoma after curative resection: prognostic factors. AJR Am J Roentgenol. 2015;204(6):1322\u20138. https:\/\/doi.org\/10.2214\/AJR.14.13343.","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"2886_CR17","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-17-2899","volume":"24","author":"Z Wang","year":"2018","unstructured":"Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24(9):2074\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2899.","journal-title":"Clin Cancer Res"},{"key":"2886_CR18","doi-asserted-by":"publisher","first-page":"615133","DOI":"10.3389\/fmolb.2021.615133","volume":"8","author":"L Chen","year":"2021","unstructured":"Chen L, Yu CX, Zhong BY, et al. Development of TACE refractoriness scores in hepatocellular carcinoma. Front Mol Biosci. 2021;8:615133. https:\/\/doi.org\/10.3389\/fmolb.2021.615133. Published 2021 Mar 26.","journal-title":"Front Mol Biosci"},{"issue":"17","key":"2886_CR19","doi-asserted-by":"publisher","first-page":"29416","DOI":"10.18632\/oncotarget.15075","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017;8(17):29416\u201327. https:\/\/doi.org\/10.18632\/oncotarget.15075.","journal-title":"Oncotarget"},{"key":"2886_CR20","doi-asserted-by":"publisher","first-page":"821599","DOI":"10.3389\/fonc.2021.821599","volume":"11","author":"B Yang","year":"2021","unstructured":"Yang B, Jie L, Yang T, et al. TACE plus lenvatinib versus TACE plus sorafenib for unresectable hepatocellular carcinoma with portal vein tumor thrombus: a prospective cohort study. Front Oncol. 2021;11:821599. https:\/\/doi.org\/10.3389\/fonc.2021.821599. Published 2021 Dec 23.","journal-title":"Front Oncol"},{"issue":"4","key":"2886_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/SLA.0000000000004350","volume":"273","author":"SW Shin","year":"2021","unstructured":"Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection versus local ablation therapies for hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis. Ann Surg. 2021;273(4):656\u201366. https:\/\/doi.org\/10.1097\/SLA.0000000000004350.","journal-title":"Ann Surg"},{"issue":"1","key":"2886_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12885-021-08033-x","volume":"21","author":"DJ Pinato","year":"2021","unstructured":"Pinato DJ, Cortellini A, Sukumaran A, et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer. 2021;21(1):301. https:\/\/doi.org\/10.1186\/s12885-021-08033-x. Published 2021 Mar 23.","journal-title":"BMC Cancer"},{"issue":"3","key":"2886_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13645706.2019.1707689","volume":"30","author":"AL Feng","year":"2021","unstructured":"Feng AL, Zhu JK, Yang Y, et al. Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC. Minim Invasive Ther Allied Technol. 2021;30(3):163\u20138. https:\/\/doi.org\/10.1080\/13645706.2019.1707689.","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"8","key":"2886_CR24","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492\u2013501. https:\/\/doi.org\/10.1136\/gutjnl-2019-318934.","journal-title":"Gut"},{"issue":"21","key":"2886_CR25","doi-asserted-by":"publisher","first-page":"18715","DOI":"10.18632\/oncotarget.4134","volume":"6","author":"X Qi","year":"2015","unstructured":"Qi X, Wang D, Su C, Li H, Guo X. Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2015;6(21):18715\u201333. https:\/\/doi.org\/10.18632\/oncotarget.4134.","journal-title":"Oncotarget"},{"issue":"4","key":"2886_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/jso.23994","volume":"112","author":"H Wu","year":"2015","unstructured":"Wu H, Liu S, Zheng J, Ji G, Han J, Xie Y. Transcatheter arterial chemoembolization (TACE) for lymph node metastases in patients with hepatocellular carcinoma. J Surg Oncol. 2015;112(4):372\u20136. https:\/\/doi.org\/10.1002\/jso.23994.","journal-title":"J Surg Oncol"},{"issue":"6","key":"2886_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","volume":"1","author":"YR Huo","year":"2015","unstructured":"Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2015;1(6):756\u201365. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2189.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2886_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/jpm12040518","volume":"12","author":"CW Huang","year":"2022","unstructured":"Huang CW, Wu TH, Hsu HY, et al. Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma. J Pers Med. 2022;12(4):518. https:\/\/doi.org\/10.3390\/jpm12040518. Published 2022 Mar 23.","journal-title":"J Pers Med"},{"issue":"1","key":"2886_CR29","doi-asserted-by":"publisher","first-page":"146045822098420","DOI":"10.1177\/1460458220984205","volume":"27","author":"D Chicco","year":"2021","unstructured":"Chicco D, Oneto L. Computational intelligence identifies alkaline phosphatase (ALP), alpha-fetoprotein (AFP), and hemoglobin levels as most predictive survival factors for hepatocellular carcinoma. Health Informatics J. 2021;27(1):1460458220984205. https:\/\/doi.org\/10.1177\/1460458220984205.","journal-title":"Health Informatics J"},{"issue":"16","key":"2886_CR30","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.7150\/ijbs.46896","volume":"16","author":"F Liu","year":"2020","unstructured":"Liu F, Guo X, Dong W, et al. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable hepatocellular carcinoma with portal vein tumor thrombus after liver resection. Int J Biol Sci. 2020;16(16):3210\u201320. https:\/\/doi.org\/10.7150\/ijbs.46896. Published 2020 Oct 23.","journal-title":"Int J Biol Sci"},{"key":"2886_CR31","doi-asserted-by":"publisher","first-page":"537526","DOI":"10.3389\/fonc.2020.537526","volume":"10","author":"LX Zhang","year":"2021","unstructured":"Zhang LX, Luo PQ, Chen L, et al. Model to predict overall survival in patients with hepatocellular carcinoma after curative hepatectomy. Front Oncol. 2021;10:537526. https:\/\/doi.org\/10.3389\/fonc.2020.537526. Published 2021 Mar 5.","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.1186\/s12876-026-04731-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000}}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02886-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02886-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02886-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:51:32Z","timestamp":1775728292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-023-02886-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02886-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"17 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12876-026-04731-7","URL":"https:\/\/doi.org\/10.1186\/s12876-026-04731-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the affiliated Hospital of Southwest Medical University, the institutional review boards of Shandong Cancer Hospital and Luxian People's Hospital, and informed consent was obtained from all subjects. All methods were carried out in accordance with guidelines and regulations related to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}